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Injury to the central nervous system (CNS) results in the formation of a highly 
inhibitory glial scar consisting mainly of chondroitin sulfate proteoglycans (CSPGs).  
CSPGs are comprised of a protein core with covalently attached chondroitin sulfate 
glycosaminoglycan (CS-GAG) side chains.  CSPGs and CS-GAGs have been implicated 
in the regenerative failure of the CNS, though the mechanism underlying inhibition is 
unclear.  Sulfation affects both the physical and chemical characteristics of CS-GAGs 
and, therefore, it has been hypothesized that certain sulfation patterns are more inhibitory 
than others.  To investigate this hypothesis, specific chondroitin sulfate sulfotransferases 
(CSSTs), the enzymes responsible for CS-GAG sulfation, were knocked down in vitro 
using siRNA.  C4ST-1, C4ST-2, and C46ST were chosen as targets for gene knockdown 
in this study based on their expression in neural tissue and the extent of inhibition caused 
by their respective CS-GAG.  It was hypothesized that transfection of primary rat 
astrocytes with siRNAs designed to prevent the expression of C4ST-1, C4ST-2, and 
C46ST would decrease specific sulfation patterns of CSPGs, resulting in improved 
neurite extension in a neurite guidance assay. Through optimization of siRNA dose, 
astrocyte viability was maintained while successfully knocking down mRNA levels of 
C4ST-1, C4ST-2, and C46ST and significantly reducing total levels of secreted CS-
GAGs. However, no increase in the incidence of neurite extension was observed using 
conditioned media collected from siRNA transfected astrocytes compared to non-
transfected controls. These data suggest that sulfation does not contribute to CSPG-
mediated neurite inhibition, though further investigation is necessary to confirm these 
 xi 
findings. Significantly, this work has established a paradigm for investigating the role of 










Spinal Cord Injury 
In the United States alone there are an estimated 12,000 new cases of spinal cord 
injury (SCI) a year, with approximately 250,000 individuals living with an injury.  The 
majority of SCIs result in permanent loss of muscle function and physical sensation 
below the area of injury, significantly reducing the quality of life and lowering the life 
expectancy of the individual.  Currently, there is no clinical treatment to regenerate the 
severed or degenerated axons of an injured spinal cord, only ways to prevent further 
damage from occurring.  Furthermore, with medical expenses and patient care costing 
between $200,000 and $700,000 in the first year and up to $3 million in a lifetime, SCI 
can be a financial hardship on both the individual and his or her family 
(www.spinalcord.uab.edu, 2008).    
 
Regenerative Failure in the CNS 
Following injury to the central nervous system (CNS) axons fail to regenerate.  
Historically, this was considered to be a property inherent to neurons of the CNS (Clark, 
1943) however, when neurons derived from the CNS are implanted in the peripheral 
nervous system (PNS), where spontaneous regeneration does occur, extensive axon 
sprouting is observed (Richardson et al., 1980; David and Aguayo, 1981).  Furthermore, 
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while limited neurite sprouting has been observed in the injured CNS (Liu and Chambers, 
1958), the growth cones quickly become dystrophic and are incapable of entering the 
lesion site (Misgeld and Kerschensteiner, 2006; Misgeld et al., 2007).  Hence, it is now 
believed that regenerative failure is due to the extrinsic molecular environment at the site 
of injury, rather than the intrinsic nature of the cells.  In particular, there are several 
classes of molecules locally released at the site of injury that are potently inhibitory to 
neuronal regeneration.   
 
Myelin Related Inhibitors 
Neurite inhibition has been largely attributed to the release of several molecules 
from disrupted CNS myelin, commonly referred to as the myelin related inhibitors.  
These molecules include myelin-associated glycoprotein (MAG) (McKerracher et al., 
1994; Mukhopadhyay et al., 1994), Nogo (Chen et al., 2000; GrandPre et al., 2000; 
Prinjha et al., 2000), and oligodendrocyte myelin glycoprotein (OMgp) (Kottis et al., 
2002; Wang et al., 2002).  Surprisingly, it was found that the neuronal receptor to Nogo, 
NgR, also binds to MAG and OMgp, suggesting that all three function through a common 
pathway (Fournier et al., 2001; Domeniconi et al., 2002; Wang et al., 2002).  Such 
findings have made myelin associated inhibitors promising therapeutic targets for 
promoting CNS regeneration. In vivo, neutralization of Nogo, using anti-Nogo antibodies 
(Bregman et al., 1995; Fouad et al., 2004) or NgR receptor antagonists (GrandPre et al., 
2002), has resulted in significantly improved axon sprouting.  Despite this, little or no 
regeneration occurs in Nogo (Simonen et al., 2003)[21], MAG (Bartsch et al., 1995), or 
NgR (Kim et al., 2004) knockout models (an OMgp KO does not exist), particularly in 
 3 
the cortical spinal tract.  For this reason, it is a generally accepted that although the 
myelin related inhibitors impede neurite outgrowth, they are not the key inhibitory 
components.  
 
Scar Related Inhibitors 
Despite the effects of myelin related inhibitors on neurite outgrowth, the primary 
cause of regenerative failure is believed to be the formation of the highly inhibitory glial 
scar, which presents both biochemical and physical barriers.  Disruption of the blood 
brain barrier (BBB) and initial cell death following injury results in substantially 
increased levels of cytokines and growth factors in the area, activating astrocytes 
(reactive astrocytes) (Eng et al., 1987) and microglia (activated microglia) (Kreutzberg, 
1996).  Consequently, production of the intermediate filament protein, glial fibrillary 
acidic protein (GFAP), is immediately upregulated in reactive astrocytes, causing the 
cells to become hypertrophic and extend filopodia, thereby generating a barrier that 
participates in the repair of the BBB, sequestering the injured area and protecting healthy 
tissue from damage (Bush et al., 1999; Faulkner et al., 2004).  Unfortunately, this barrier 
is not permissive to axon growth, and, in turn, prevents functional recovery after injury.  
Hence, the glial scar acts as both a physical and chemical barrier to axonal regeneration; 
the dense meshwork of hypertrophic cells and extracellular matrix physically impede 
growth cone migration (Windle and Chambers, 1950), while inhibitory molecules 
secreted by reactive astrocytes and activated microglia, namely chondroitin sulfate 
proteoglycans (CSPGs) (Fawcett and Asher, 1999), generate a biochemical barrier to 
axonal regeneration (McKeon et al., 1991). 
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Chondroitin Sulfate Proteoglycans 
Structure and Synthesis 
CSPGs consist of a protein core with a variable number of chondroitin sulfate 
glycosaminoglycan (CS-GAG) side chains covalently attached to serine residues.  CS-
GAGs are unbranched polysaccharide chains comprised of repeating disaccharides of 
glucuronic acid (GlcUA) and galactosamine (GalNAc).  These chains can be further 





(PAPS) onto the disaccharide’s hydroxyl groups (Silbert and Sugumaran, 2002).  
Monosulfated GAGs result from the sulfation at the 4 or the 6 carbon of GalNAc (CS-4 
and CS-6, respectively) and disulfated GAGs result from the sulfation at either the 2 
carbon of GlcUA and the 6 carbon of GalNAc (CS-2,6), or at both the 4 and the 6 
carbons of GalNAc (CS-4,6) (Figure 1.1).   
It is difficult to isolate pure forms of the specific CS-GAGs given that in nature 
individual CS-GAG chains usually consist of a combination of the various disaccharides.  
The commercially available CS-GAGs are mixtures of the dissacharides, though CS-A 
and CS-B (or dermatan sulfate) consist mostly 4-sulfated chains, CS-C consists mostly 6-
sulfated chains, CS-D consists mostly of 2,6 sulfated chains, and CS-E consists mostly of 
4,6 sulfated chains.  In dermatan sulfate the GlcUA is epimerized to iduronic acid (Silbert 
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Figure 1.1.  Chondroitin Sulfate Disaccharide Unit.  CS-GAG chains are comprised of 
repeating disaccharides of glucuronic acid and galactosamine.  The disaccharide is 





The biosynthesis of CS-GAG chains occurs with the aid of multiple enzymes 
(Figure 1.2), beginning with the addition of xylose (Xyl) to a serine residue on the core 
protein, followed by the addition of two galactose (Gal) residues, and a glucuronic acid 
residue (GlcUA), forming the tetrasaccharide linkage region (Ser[ Xyl-Gal-Gal-GlcUA]-) 
common to all chondroitin, dermatan, and heparan sulfates.  Each of these sugars is 
successively added by a specific glycosyltransferase (xylose transferase-I (XT-I) (Gotting 
et al., 2000), galactose transferase-I (GalT-I) (Almeida et al., 1999), galactose 
transferase-II (GalT-II) (Bai et al., 2001), glucuronic acid transferase-I (GlcUAT-I) 
(Kitagawa et al., 1998), respectively).  Next, a fifth glycosyltransferase, GalNAc 
transferase-I (GalNAcT-I), adds a GalNAc residue, thereby committing the proteoglycan 
to becoming a CS-GAG (Silbert and Sugumaran, 2002).  Chain polymerization continues 
by the addition of alternating GlcUA and GalNAc residues through a complex consisting 
of chondroitin synthase (ChSy) and chondroitin polymerizing factor (ChPF).  ChSy is 
responsible for synthesizing the disaccharides (Kitagawa et al., 2001) whereas ChPF is 
responsible for chain polymerization (Kitagawa et al., 2003).   
 During chain polymerization, CS-GAGs are further modified by the sulfation of 
the disaccharides with the aid of specific chondroitin sulfate sulfotransferases (CSSTs) 
(Figure 1.3).  4 and 6 sulfation occurs through one of three chondroitin 4-
sulfotransferases (C4ST-1 (Hiraoka et al., 2000; Mikami et al., 2003), C4ST-2 (Hiraoka 
et al., 2000; Mikami et al., 2003), or C4ST-3 (Evers et al., 2001) or one of two 
chondroitin 6-sulfotransferases (C6ST-1 (Fukuta et al., 1995; Uchimura et al., 1998) or 
C6ST-2 (Kitagawa et al., 2000)), respectively.  N-acetylgalactosamine 4-sulfate 6-O-
sulfotransferase (C46ST) sulfates the 6 hydroxyl of a preexisting CS-4 to form CS-4,6 
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(Ito and Habuchi, 2000), and uronyl-2-sulfotransferase (UST) sulfates the 2 hydroxyl of a 




Figure 1.2.  Enzymes in CS-GAG Chain Biosynthesis. Many enzymes aid in the 
biosynthesis of CS-GAG chains.  XT-1 initiates synthesis by adding a Xyl to a Ser on the 
core protein.  GalT-I, GalT-II, and GlcUAT-I then successively add 2 Gals and GlcUA, 
respectively,   forming the tetrasaccharide linkage region (Ser-[Xyl-Gal-Gal-GlcUA]) 
common to all proteoglycans.  Next, GalNAcT-I adds a GalNAc, thereby committing the 
proteoglycan to becoming a CS-GAG.  Chain polymerization continues by the addition of 
alternating GlcUA and GalNAc residues through a complex consisting of ChSy, which is 
responsible for synthesizing the disaccharides, and ChPF which is responsible for chain 







Figure 1.3.  Chondroitin Sulfate Sulfotransferases.  Sulfates are added to each position of 
chondroitin sulfate with the aid of specific CSSTs.  4-sulfation occurs through one of 
three chondroitin 4-sulfotransferases (C4ST-1, C4ST-2, or C4ST-3).  6- sulfation occurs 
through one of two chondroitin 6-sulfotransferases (C6ST-1 or C6ST-2).  N-
acetylgalactosamine 4-sulfate 6-O-sulfotransferase (C46ST) sulfates the 6 hydroxyl of a 
preexisting CS-4 to form CS-4,6.  Uronyl-2-sulfotransferase (UST) sulfates the 2 






The ability for cells to create such diverse structures through modifying chain 
length and CS-GAG disaccharide composition has resulted in several distinct biological 
functions of CSPGs.  These molecules have been implicated in growth factor signaling 
(Deepa et al., 2002), wound healing (Yeo et al., 1991), inflammation (Taylor and Gallo, 
2006), cell division (Bechard et al., 2001), and tissue morphogenesis (Hwang et al., 
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2003).  In cartilage CSPGs are vital for the tissue’s ability to resist high compressive 
loading.  This is due to the net negative charge of the CS-GAGs, which allows them to 
hold in water molecules causing the tissue to create an osmotic swelling pressure (Bayliss 
et al., 1999).  In the developing CNS, CSPGs act as repulsive cues in cell migration 
(Nishizuka et al., 1996) and define barriers for extending neurites (Brittis et al., 1992).  
Additionally CSPGs appear to play an important role in CNS plasticity and are a major 
component of perineuronal nets (Celio and Blumcke, 1994).  Following injury to the 
CNS there is a significant upregulation of CSPG production, predominantly by reactive 
astrocytes, forming the highly inhibitory glial scar.  
CSPGs often function through their interactions with various growth factors, cell 
adhesion molecules, enzymes, and ECM components.  The ability for CSPGs to interact 
with these molecules is dependent on their specific CS-GAG content.   
 
CSPGs in Regenerative Failure 
The inhibitory role of CSPGs in axonal regeneration has been clearly 
demonstrated both in vitro (McKeon et al., 1995; Meiners et al., 1995) and in vivo 
(Zhang et al., 2001), however, the mechanism by which inhibition occurs is poorly 
understood.  In particular, there is much debate over whether the CS-GAGs or the protein 
core contribute more to inhibition.  Certain CSPGs, such as brevican (Yamada et al., 
1997), phosphacan (Sango et al., 2003) and neurocan (Talts et al., 2000; Sango et al., 
2003), lose at least some of their inhibitory capabilities following treatment with 
chondroitinase ABC (chABC), suggesting a CS-GAG mediated inhibition, whereas other 
CSPGs, such as NG2 (Dou and Levine, 1994) and versican (Schmalfeldt et al., 2000), do 
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not, suggesting a protein core mediated inhibition.  Furthermore, studies investigating the 
effects of isolated CS-GAGs on neurite outgrowth in vitro have produced conflicting 
results.  Some have reported CS-GAGs to be inhibitory to neurite outgrowth (Brittis and 
Silver, 1994; Becker and Becker, 2002), whereas others have observed the opposite 
(Faissner et al., 1994; Fernaud-Espinosa et al., 1994; Challacombe and Elam, 1997; 
Nadanaka et al., 1998; Clement et al., 1999). An explanation for this inconclusive data is 
that in these experiments no distinction was made between soluble and substrate bound 
CS-GAGs, and  previously it has been shown that substrate bound CSPGs inhibit neurite 
outgrowth whereas soluble CSPGs do not (Snow et al., 1996).  Because of their highly 
hydrophilic nature, CS-GAGs are not readily immobilized via adsorption, and are 
therefore difficult to study in a substrate bound form.  When neurite extension was 
measured from cells grown in 3D hydrogels with CS-GAGs covalently attached 
(ensuring CS-GAG immobilization) all three CS-GAGs explored (CS-B, CS-C, CS-E) 
demonstrated an inhibitory effect (Gilbert et al., 2005).  Furthermore, the extent of 
inhibition was dependent on sulfation position and degree of sulfation.  The greatest 
contributor to inhibition was CS-E, which was comparable to the full CSPG, followed by 
CS-B (Gilbert et al., 2005).  These data suggests that not only do the CS-GAGs 
contribute to CSPG-mediated inhibition, but that sulfation also plays a major role in this 
function. 
 
CS-GAG Composition in Development and After Injury  
The composition of CS-GAG disaccharides changes throughout development.  
Specifically, the percentage of CS-GAGs either non-sulfated or 4-sulfated increases from 
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84% in embryonic rat cortical tissue to 96% in adult tissue and the percentage of 6-
sulfated CS-GAGs decreases from 14% in embryonic tissue to 2% in adult tissue 
(Properzi et al., 2005).    Additionally, CS-GAG disaccharide composition changes after 
injury.  Most notably, CS-4,6, which is nearly undetectable in uninjured tissue is 
significantly upregulated in adult cortical scar tissue (Gilbert et al., 2005).  Given that the 
ability for CNS neurons to regenerate decreases throughout development (Dusart et al., 
1997) and that the environment in the CNS after injury is highly inhibitory, this suggests 
that the inhibitory properties of CSPGs may be dependent on disaccharide composition.  
Specifically, CS-4 and CS-4,6 may be particularly inhibitory given that the percentage at 
which they are present increases as regenerative capacity decreases.  Collectively, these 
data corroborate previous findings indicating that CS-4,6 is the most inhibitory CS-GAG 
followed by CS-4 (Gilbert et al., 2005).   
 
Chondroitinase ABC 
 Chondroitinase ABC (chABC) is an enzyme purified from the bacterium Proteus 
vulgaris that degrades chondroitin sulfate (Yamagata et al., 1968).  ChABC consists of an 
endoeliminase that depolymerizes chondroitin sulfate and an exoeliminase that breaks 
down tetra- and hexasaccharides into disaccharides (Hamai et al., 1997).  The ABC in the 
name refers to CS-A, CS-B, and CS-C, though the enzyme is also effective in cleaving 





Therapeutic Applications of chABC 
The delivery of chABC in vivo has resulted in a promising increase in axonal 
sprouting (Moon et al., 2001; Bradbury et al., 2002).  However, several disadvantages are 
associated with the use of this enzyme clinically.  First, the cleavage of CS-GAGs by 
chABC is non-specific and, consequently, all CSPGs at the site are degraded, including 
those necessary for proper CNS function, namely CSPGs involved in the formation of 
perineuronal nets (Bruckner et al., 1998).  In addition, chABC is incapable of digesting 
the initial tetrasaccharide that is added to the core protein to begin CS-GAG chain 
synthesis, resulting in the presence of an “inhibitory stub” (Caterson et al., 1985; Lemons 
et al., 2003).  Moreover, the enzymatic activity of chABC is short lived in vivo, and 
therefore multiple injections are necessary to achieve sufficient degradation (Tester et al., 
2007).  Finally, because chABC is a bacterial enzyme (Yamagata et al., 1968) and no 
mammalian equivalents currently exist, repeated dosing necessary for effective cleavage 




Small interfering RNAs (siRNAs) are short nucleic acid sequences, 21 to 23 base 
pairs in length, which are capable of post transcriptional gene silencing by inducing the 
degradation of complimentary mRNA sequences.  siRNA is an integral component of the 
RNA interference (RNAi) pathway, an evolutionarily conserved mechanism that protects 
the genome from foreign genetic elements.  More specifically, this pathway degrades 
potentially harmful double stranded RNA (dsRNA), such as those found in cells infected 
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by a virus.  When dsRNA is detected in a cell, Dicer, a cytoplasmic ribonuclease III-like 
enzyme, cleaves it into 21 to 23 nucleotide fragments (siRNAs).  These siRNA then bind 
to a multiprotein complex called RNA-induced silencing complex (RISC), where the 
dsRNA is linearized and the strands are separated.  The single stranded RNA bound to 
RISC, or the guide strand, then complexes with complimentary mRNA.  The mRNA is 
cleaved by Argonaute 2, an enzyme present in RISC, thereby preventing translation of 
the transcript.  Once mRNA degradation is complete, the guide strand remains bound to 
RISC, allowing for the complex to bind with additional mRNA, thereby amplifying the 
degradation of the target mRNA (Figure 1.4) (Aagaard and Rossi, 2007).  
  
Applications of siRNA 
Recently, the RNAi pathway has proven to be a powerful tool in studying the 
function of specific genes both in vitro (Scherr et al., 2003) and in vivo (Lingor and Bahr, 
2007).  Cells can be infected with a vector that is processed into short hairpin RNA 
(shRNA) containing 21-base pair dsRNA which are cleaved by Dicer into siRNA.  
Alternatively, synthetic siRNA can be transfected into cells which thereby directly 
activates RISC.  The success in silencing specific genes has sparked much interest in 





Figure 1.4.  Mechanism of siRNA.  SiRNAs are short nucleotide sequences that induce 
the degradation of complimentary mRNA sequences.  DsRNA detected in the cell is 
cleaved by Dicer into 21 to 23 nucleotide siRNAs.  These siRNA then bind to RISC, 
where the strands are separated.  The single stranded RNA bound to RISC (the guide 
strand) complexes with complimentary mRNA.  The mRNA is cleaved by an enzyme 
present in RISC, thereby preventing translation of the transcript.  Once mRNA 
degradation is complete, the guide strand remains bound to RISC, allowing for the 
complex to bind with additional mRNA, thereby amplifying the degradation of the target 
mRNA.  Synthetic siRNAs introduced into the cells can are potential therapeutic agents. 
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Recent Work in Modifying CS-GAG Chain Synthesis 
 An alternative approach to using chABC in removing inhibitory CS-GAGs from 
the injury site is to alter CSPG producing cells.  In particular, astrocytes can be 
genetically engineered to secrete CSPGs without CS-GAGs or with modified CS-GAGs 
by knocking down the enzymes responsible for CS-GAG chain synthesis. 
 
Xylosyl-Transferase-1  
One approach that has been examined is to knockdown XT-1 in vivo by locally 
delivering a DNA enzyme which specifically degrades XT-1 mRNA (Grimpe and Silver, 
2004), thereby preventing glycosylation in the cells that uptake the enzyme.  This 
approach was successful at reducing CS-GAG intensity at the lesion penumbra, and 
neurites were able to regenerate around the injury site.  However, because xylose is part 
of the tetrasaccharide common to all sulfated proteoglycans, not only CSPGs, this 
enzyme is not an ideal target.   In particular, several HSPG (heparan sulfate 
proteoglycans) binding proteins have been implicated in the promotion of neurite 
outgrowth (Kinnunen et al., 1996), and, therefore, preventing HSPG chain 
polymerization is not favorable.  
 
Chondroitin Polymerizing Factor  
In a recent study, siRNA was used to knock down ChPF in an astrocytic cell line 
in vitro. Preventing CS-GAG chain polymerization was as effective as chABC in 
reducing the inhibitory properties of the conditioned astrocyte media (Laabs et al., 2007).  
Neurites from primary neurons grown on spots made from conditioned media of siRNA 
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treated cells were able to cross into the spot more readily than those grown on control 
spots.  Although these results are promising, this approach, as with chABC, leaves behind 
an “inhibitory stub” on the CSPGs (Lemons et al., 2003).      
  
Purpose of Thesis Project 
The objective of this thesis was to explore the use of siRNA as an alternate 
therapy to chABC for promoting axonal regeneration after injury to the CNS.  Sulfation 
affects both the physical and chemical characteristics of CS-GAGs and, therefore, it has 
been hypothesized that certain sulfation patterns may be more inhibitory than others.  To 
investigate this hypothesis, specific CSSTs, the enzymes responsible for CS-GAG 
sulfation, were knocked down in vitro using siRNA.  C4ST-1, C4ST-2, and C46ST were 
chosen as targets for gene knockdown in this study based on their expression in neural 
tissue and the extent of inhibition caused by their respective CS-GAG.  C6ST-1 and and 
it’s CS-GAG, CS-6, are both upregulated after injury (Properzi et al., 2005), though 
neither C6ST was chosen as a target for knockdown as CS-6 is the least inhibitory of all 
of the CS-GAGs (Gilbert et al., 2005).  Although there are three known sulfotransferases 
responsible for CS-4 sulfation, only C4ST-1 and C4ST-2 are explored herein.  In humans, 
C4ST-3 is expressed in the liver and kidney and is not found in neural tissue (Kang et al., 
2001), whereas the expressions of C4ST-1 and C4ST-2 are more widespread (Hiraoka et 
al., 2000). This finding has been verified in mice (Akita et al., 2007).  Therefore, it was 
hypothesized that transfection of primary rat astrocytes with siRNAs designed to prevent 
the expression of C4ST-1, C4ST-2, and C46ST would decrease specific sulfation patterns 
secreted by these cells. Conditioned culture media from the transfected astrocytes was 
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collected and used in neurite growth assays to determine the effect of sulfation on neurite 
extension.    
 
Hypothesis 
Successful treatment of the injured spinal cord must overcome the inhibitory 
effects of the glial scar while maintaining its beneficial properties.  The central 
hypothesis of this thesis is that specific CS-GAG sulfation patterns, in particular CS-4 
and CS-4,6, dictate the inhibitory properties of CSPGs, and that modulation of sulfation 
patterns will promote neurite extension. 
 
 Objectives 
The overall objective of this thesis research is to determine if neurite inhibition can be 
alleviated through modulating CS-GAG sulfation.  To test this hypothesis, the following 
objectives were set:  
 1. Knockdown CSSTs in astrocytes in vitro using siRNA  




MATERIALS AND METHODS 
 
Cell culture 
Astrocyte Isolation and Culture 
Primary cortical astrocytes were harvested from the brains of postnatal day 1 rat 
pups (Harlan).  The pups were anesthetized with isoflurane (Henry Schein), decapitated, 
and the brain was removed.  The cerebral cortices were microdissected out and the 
meninges were removed.  The isolated cortical tissue was then minced and stored in 
Leibovitz’s L-15 media (Invitogen).  The tissue was digested by subsequent incubations 
with 0.25% collagenase (type 4) (Worthington Biochemical Corporation) and 0.25% 
trypsin and then dissociated by mechanically disrupting the digested tissue with a 
micropipette tip. Dissociated cells were plated in a T75 flask containing Dulbecco’s 
Modified Eagle’s Media/Ham’s F-12 50/50 Mix (DMEM/F12; Mediatech) containing 
10% fetal bovine serum (FBS; Hycolone) and 1% penicillin streptomycin (PS; MP 
Biomedicals).  The astrocyte cultures were purified by mechanically removing neurons 
and microglia at 24 and 72 hours.  Cultures were passaged at 90% confluency and 
maintained in T225 flasks.  Unless otherwise noted, cells were used between passage 4 
and passage 7 for experiments. 
 
Cortical Neuron Isolation and Culture 
Primary cortical neurons were harvested from the brains of rat fetuses (Embryonic 
day 18).  Timed pregnant Sprague Dawley rats were anesthetized using isoflurane and 
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then rapidly decapitated.  The uterus was removed by caesarean section, and the pups 
were removed from the amniotic sac into ice cold hank’s balanced salt solution (HBSS) 
where they were then quickly decapitated.  The brains were removed from the fetuses, 
freed from meninges and the cortical tissue was isolated by microdissection.  The isolated 
tissue was digested with 0.25% trypsin EDTA for 10 minutes at 37
o
C and then 
dissociated through trituration in the presence of 0.15mg/mL deoxyribonuclease I 
(DNase; Sigma) in HBSS. Viability and concentration of dissociated cells was 
determined using the trypan blue exclusion assay.  For neurite outgrowth assays, cells 
were resuspended in Neurobasal containing B27 supplement (Invitrogen), 500µM l-
glutamine (Hyclone), and 1% PS, and plated at 35,000 cells/cm
2
.   
 
Transfection of Astrocytes with siRNA 
Quantification of Transfection Efficiency 
The transfection efficiency of primary rat astrocytes with FuGENE®HD 
Transfection Agent (Roche), was assayed using siGLO® Green Transfection Indicator 
(Dharmacon).  24 hours prior to transfection, astrocytes were removed from tissue culture 
flasks by trypsinization and plated onto 6-well plates in complete growth medium.  3X10
5
 
cells were plated per well and 3 wells were plated per condition.  Just prior to 
transfection, media was removed and replaced with serum free DMEM/F12.  For each 
condition 300 L (100 L/well) of serum free media was added to a microcentrifuge tube.  
To these tubes siRNA (12 L total, 4 L/well) and FuGENE (12 L total, 4 L/well) were 
added and allowed to complex by incubating for 15 minutes at room temperature.  100 L 




incubator.  After 48 hours, one set of the cells was again transfected using the same 
protocol.  After 72 hours, the cells were washed 3 times with PBS, fixed with 4% 
paraformaldehyde, and stained with  4',6-diamidino-2-phenylindole (DAPI; Invitrogen), 
in order to visualize nuclei.  A random image was taken of each well at 10X 
magnification with a Zeiss Axiovert 200M microscope using the DAPI and FITC filters.  
Images were overlaid in Adobe Photoshop.  Transfection Efficiency was defined as the 
percentage of cells with green siRNA was colocalized with the nucleus.       
 
Determination of Optimal siRNA Concentration 
SiRNA is toxic to cells at high concentrations and ineffective at sufficiently 
silencing gene expression at low concentrations (Reynolds et al., 2004).  The ensuing 
studies knockdown three genes simultaneously; therefore, in order to minimize total 
siRNA concentration a dosing study was performed to determine the lowest 
concentration of each CSST siRNA that is still effective for significant silencing.  In 
order to maximize mRNA degradation, for each gene, a pool of four siRNA constructs 
complimentary to four separate locations on the mRNA strand was used.  The siRNA 
against C4ST-1 was ON-TARGETplus SMARTpool siRNA (Dharmacon), which is a 
premade pool of the four siRNA sequences.  For C4ST-2 and C46ST, four separate 
siGENOME siRNA (Dharmacon) sequences were purchased and later pooled.   In total, 
four concentrations of the C4ST-1 siRNA were examined; 0, 40, 60, and 80nM, and five 
concentrations of the C4ST-2 and C46ST siRNA were examined; 0, 40, 60, and 80nM, 
and 100nM (0, 10, 15, 20, and 25nM of individual sequences). Cells were transfected 
(n=3) at both 24 and 48 hours after plating using the protocol as described above.  After 
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72 hours, the cells were lysed and RNA was extracted using the RNeasy Mini Kit 
(Qiagen).  Successful knockdown was defined at mRNA levels 20% or less of control.    
 
Knockdown of C4ST-1, C4ST-2, and C46ST 
The ability to down regulate the chondroitin-4 sulfotransferases C4ST-1, C4ST-2, 
and the chondroitin-4,6 sulfotransferase C46ST in vitro was assayed using siRNA 
specifically designed to the transcripts.  24 hours prior to transfection, astrocytes were 
removed from tissue culture flasks by trypsinization and plated onto 6-well plates in 
complete growth medium.  4X10
5
 cells were plated per well, three wells were plated per 
condition, and the experiment was run two times.  Cells were transfected both 24 and 48 
hours after plating using the protocol as described above.  The amount of siRNA used for 
each condition was what was determined in the previous section as being the lowest 
concentration that results in sufficient knockdown (Table 2.1).  72 hours post transfection 
conditioned media (CM) was collected and stored at -80
o
C for future analysis and RNA 
was extracted from the cells.  72 hours was chosen as the endpoint because by this time 
the effects of the siRNA are detected and the astrocytes should be able to secrete an 
adequate amount of CSPGs.  Each sulfotransferase was assayed separately, as well as a 
combination of the chondroitin-4 sulfotransferases (C4ST-1, C4ST-2), and all three 
sulfotransferases (C4ST-1, C4ST-2, C46ST).   
To explore the kinetics of CS-GAG sulfation an additional study was performed 
where the media was changed 24 hours post transfection and then collected 72 hours post 
transfection.  The purpose of this study was to reduce the amount of secreted CS-GAGs 
that were produced before CSST protein levels were decreased.  In this experiment there 
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were six conditions: Control (no media change), Control (media collected at 24 hours), 
Control (media change at 24 hours, media collected at 72 hours), Triple KD (no media 
change), Triple KD (media collected at 24 hours), and Triple KD (media change at 24 
hours, media collected at 72 hours).  For each condition 4X10
5
 cells were plated per well, 
three wells were plated per condition, and the experiment was run one time.  The 
astrocytes used in this experiment were passage 12. 
 
Table 2.1.  SiRNA Doses.  For each experimental condition the lowest concentration of 




siRNA/well  FuGENE/ 
well C4ST-1 C4ST-2 C46ST Total 
Control 
0nM 0nM 0nM 0nM 
4 L 
0 L 0 L 0 L 0 L 
C4ST-1 
60nM 0nM 0nM 60nM 
4 L 

















































Quantification of the Effects of siRNA Mediated Gene Silencing 
Quantitative RT- PCR 
Successful gene silencing was verified by reverse transcription quantitative 
polymerase chain reaction (qRT-PCR).  72 hours post-transfection, mRNA was extracted 
from the cells using the RNeasy Mini Kit (Qiagen) according to manufacturer’s protocol.  
The concentration and purity of extracted RNA was calculated by measuring the 
absorbance of the RNA at 260nm and 280nm using a spectrophotometer.  mRNA (0.5 g) 
from each condition was reverse transcribed into cDNA using an iCycler thermocycler 
(Bio-Rad) and the iScript™ cDNA Synthesis Kit (Bio-Rad) according to manufacturer’s 
protocol.  The cDNA products were stored at -20
o
C or used immediately for qRT-PCR.  
cDNA for each gene of interest was amplified for use in a standard curve by RT-PCR 
using the thermocycler.  qRT-PCR was carried out with the MyiQ Single-Color Real-
Time PCR Detection System (Bio-Rad) using IQ SYBR Green Supermix (Bio-Rad).  The 
following protocol was used: activation step, 3 min at 95
o
C; three-step cycling (40 
cycles): denaturation, 30 s at 95
o
C, annealing, 30 s at 55
o
C, extension, 1 min at 72
o
C.  A 
melt curve was subsequently performed to confirm that there was no primer dimer 
formation in the PCR products, which began at 55
o





increments.  A standard curve for each gene of interest was performed every time the 
gene was analyzed, and used to obtain the relative quantity of the targeted gene for all 
samples.  The following primer sequences were used: C4ST-1, Forward 
ACCTGAAGTTCCCCACCTATG, Reverse TTGGCACTGAGTAGTTGAACATTA, 
C4ST-2 Forward AGGCAACAGCTCTATAAACTCT, Reverse 
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ATTCTCAAAGGACCATCTCAGT; C46ST Forward 
ATAACAATGCCTGGACCTTCTTCT, Reverse GATCCCTGAGCATGACAAGGAG. 
 
Neurite Guidance Assays 
To determine if modulating CS-GAG sulfation patterns is effective in alleviating 
CSPG-mediated neurite inhibition, neurite guidance assays were performed.    CM 
collected from siRNA treated and control astrocytes was concentrated (30 fold) using a 
YM-30 centrifugal filter (Millipore).  The total protein concentration of the 
unconcentrated CM from each experimental condition was determined by using Protein 
Assay Dye Reagent (Bio-Rad) and comparing to a standard curve generated with bovine 
serum albumin (BSA; Sigma).  It was assumed that no protein was lost during 
concentrating and the final volume of concentrated product was brought up so that the 
total protein concentration in each sample was 1200 g/mL.  The concentrated CM was 
mixed 50:50 (by volume) with 1mg/mL Texas Red labeled Dextran (Invitrogen) (final 
concentration of CM 600 g/mL and Texas Red 500 g/mL) for visualization purposes.  A 
3 L drop of the CM was spotted onto a 12mm poly-L-lysine (PLL) coated glass 
coverslip placed into the well of a 24 well plate, incubated at 37
o
C in humidity for 2 
hours, and then rinsed with sterile PBS.  This created a distinct boundary between the 
PLL and the proteins in the CM that had adsorbed to the surface.  Cortical neurons were 
seeded onto the coverslips (70,000/well, n=6) in Neurobasal media supplemented with 
B27 and l-glutamine.  The cells were plated so that they covered the entire coverslip.  
After 48 hours, the cells were fixed using 4% paraformaldehyde and stained with anti-
MAP2 antibody (1:500, Chemicon) at 4
o
C overnight.  For secondary detection the cells 
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were then incubated for 2 hours with Alexa Fluor® 488 goat anti-mouse IgG1 (1:220, 
Molecular Probes).  Montages at 20X magnification were taken with a Nikon Eclipse 80i 
microscope using Neurolucida software.  Percent crossing was determined by dividing 
the number of neurites that cross over from PLL onto the spot by the total number of 
neurites within the distance of the size of one soma of the boundary.     
To verify that CSPGs did adhere to the tissue culture plates, separate spots using 
control astrocyte media were made as described above.  The coverslips were fixed with 
4% paraformaldehyde and stained with CS-56 (Sigma), an antibody specific to 
chondroitin sulfate.  The primary antibody (CS-56) was used at a 1:200 dilution and 
incubated at 4
o
C overnight.  The secondary antibody (Alexa Fluor® 488 goat anti-mouse 
IgM) was used at a 1:220 dilution and incubated 2 hours at room temperature.  After 
staining, fluorescent images using both FITC and Texas Red filters were taken of the 
coverslips using a Zeiss 200M microscope.  Images were overlaid using Adobe 
Photoshop to show colocalization of Texas Red and CS-56. 
 
Enzyme-Linked Immunosorbent Assay 
An enzyme-linked immunosorbent assay (ELISA) was performed on conditioned 
astrocyte media to determine if knocking down CSST expression has an effect on the CS-
GAG content of proteins secreted by these cells.  The total protein concentration of the 
CM from each experimental condition was determined by using Bio-Rad Protein Assay 
Dye Reagent and comparing to a standard curve generated using BSA.  The volume of 
unconcentrated CM containing 1 g of total protein was brought up to 200 L so that 
each sample was at a concentration of 5 g/mL.  50 L of these samples was added to the 
 26 
wells (n=3 for each media sample) of a nitrocellulose-coated 96-well assay plates in 
triplicate.  Nitrocellulose-coated plates were made by adding 20 L of a 
nitrocellulose/methanol solution (5cm
2
 nitrocellulose (Schleicher and Schull) in 12mL 
methanol (Fisher)) to each well and drying the solution in a laminar flow hood.  The 
proteins in the CM were allowed to adsorb to the assay plate for 6 hours at room 
temperature.  After incubation and removal of the excess CM, nonspecific background 
was blocked by adding 200 l of blocking solution (2% powdered milk in TBST) for 1 
hour at room temperature.  CS-56 (1:1000) was then added and incubated overnight at 
4
o
C.  Wells were washed 6 times with TBST and incubated with HRP-conjugated goat 
anti-mouse IgM (1:1000, Jackson Immunochemicals) for 1.5 hours.  Next, the wells were 
washed 6 times with TBST and then incubated with 200 L of substrate solution (200 L 
of 15mg/mL 2,2’-azino-bis-(3-benzthiazoline-6-sulfonic acid) (ABTS, Southern Biotech) 
and 10 L of 30% H2O2 in 10mL 50mM citrate monohydrate (Sigma))  at room 
temperature for 30 minutes and the absorbance 410 nm was recorded.  ChABC treated 
CM from control astrocytes were used at a positive control and serum free media was 





Optimization of Conditions for CSST siRNA Transfection 
 
siRNA Transfection Efficiency 
The efficiency in which the FuGENE HD/siRNA complex is transfected into 
primary rat astrocytes was assayed by transfecting the cells with an siRNA sequence 
chemically modified with a green fluorescent dye.  72 hours post-transfection, the cells 
were fixed with 4% paraformaldehyde and stained with DAPI.  Fluorescent images were 
taken at a random field in each well (n=3wells/condition) at 10X magnification using 
DAPI and FITC filters and the images were overlaid in Adobe Photoshop.  Transfection 
Efficiency was determined by counting the number of nuclei colocalized with green dots, 
indicative of siRNA in the cells (Figure 3.1).  The conditions assayed were Control Cells 
(no siRNA, no FuGENE), FuGENE Control (no siRNA), siRNA Control (no FuGENE), 
Single Transfection (transfected at t=0), and Double Transfection (transfected at t=0 and 
t=48 hours).  For both the Control Cell and FuGENE Control conditions, 0% of the cells 
contained siRNA, confirming that the positive green signal was not due to 
autofluorescence.  For siRNA Control only 1% (± 1%) of the cells contained siRNA.  
This demonstrates that a transfection agent is necessary for adequate uptake.  84% (± 
17%) of the Single Transfection cells were positive for siRNA after 72 hours whereas 
99% (±2%) of the Double Transfection cells contained siRNA.  For this reason, it was 




Figure 3.1. Transfection Efficiency of Primary Rat Astrocytes.  Transfection efficiency 
was calculated by dividing the number of nuclei colocalized with the green fluorescent 
siRNA by the total number of nuclei.  A) Control Cells (no siRNA, no FuGENE), B) 
FuGENE Control (no siRNA), C) siRNA Control (no FuGENE), D) Single Transfection 
(transfected at t=0), E) Double Transfection (transfected at t=0 and t=48 hours), F) 




Optimal Concentrations of C4ST-1, C4ST-2, and C46ST siRNA 
SiRNA is cytotoxic at high concentrations but ineffective at sufficiently knocking 
down gene expression at low concentrations.  Because subsequent studies include the 
simultaneous knockdown of three genes, a dosing study was performed to determine the 
lowest concentration of each CSST siRNA that is effective for significant gene silencing 
so that total siRNA concentration could be minimized.  In total, four concentrations of the 
C4ST-1 siRNA were examined; 0nM, 40nM, 60nM, and 80nM, and five concentrations 
of the C4ST-2 and C46ST siRNA were examined; 0nM, 40nM, 60nM, 80nM, and 
100nM.  For all conditions, astrocytes were transfected at t=0 and t=48 hours.  After 72 
hours the cells were lysed, RNA was extracted, and qRT-PCR was performed to 
determine mRNA levels of the CSST being knocked down (Figure 3.2).  To verify that 
the observed knockdown was specific to the gene of interest, qRT-PCR was also carried 
out for C4ST-2 in the C4ST-1 knockdown, C4ST-1 in the C4ST-2 knockdown, and 
C4ST-1 in the C46ST knockdown.  Successful knockdown was defined as mRNA levels 
20% or less of control.  Each PCR reaction was run in triplicate and significance from 
control was determined using the Student’s T-test.  In the C4ST-2 and C46ST 
knockdowns all conditions were significant from control (p < 0.05).  In the C4ST-1 
knockdowns, the 40nM dose was not significant from control (p > 0.05) but 60nM and 
80nM were (p < 0.05).     
C4ST-1 siRNA was most effective with the 80nM dose though successful 
knockdown was also present with the 60nM dose.  In order to minimize total siRNA 
concentration in the triple knockdown, it was decided to use the C4ST-1 siRNA at 60nM 
in subsequent studies.  For both C4ST-2 and C46ST, the siRNA significantly knocked 
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down gene expression at the lowest concentration assayed (40nM).  Therefore in 




Figure 3.2.  SiRNA Dosing.  The effectiveness of siRNA at different concentrations was 
determined for C4ST-1, C4ST-2, and C46ST siRNA using qRT-PCR. Successful 
knockdown was defined as mRNA levels 20% the control or lower.  A) C4ST-1 mRNA 
expression after transfection with C4ST-1 siRNA.  B) C4ST-2 mRNA expression after 
transfection with C4ST-1 siRNA.  C) C4ST-2 mRNA expression after transfection with 
C4ST-2 siRNA.  D) C4ST-1 mRNA expression after transfection with C4ST-2 siRNA.  
E) C46ST mRNA expression after transfection with C46ST siRNA. F) C4ST-2 mRNA 
expression after transfection with C46ST siRNA. 
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Functional Outcomes of CSST Knockdown Experiment 
 
CSST mRNA is Down-Regulated with CSST Specific siRNA 
Previous work has shown that CS-GAGs are inhibitory to neurite outgrowth, even 
in the absence of a protein core, and that the dual sulfated CS-GAG, CS-4,6, is the most 
inhibitory CS-GAG followed by CS-4 (Gilbert et al., 2005).  To establish if CS-GAG 
sulfation patterns can be modulated by silencing the expression of specific CSSTs, and if 
this modification is sufficient in suppressing CSPG mediated inhibition of neurite 
outgrowth, the genes for three CSSTs were knocked down in primary rat astrocytes in 
vitro using siRNA designed to the target mRNA.  Specifically, the chondroitin-4 
sulfotransferases C4ST1, C4ST2 and the chondroitin-4,6 sulfotransferase C46ST were 
chosen as targets since these enzymes are responsible for sulfating the most inhibitory of 
the CS-GAGs.     
For this study, each of the three sulfotransferases was knocked down separately, 
as well as a combination of the chondroitin-4 sulfotransferases (C4ST-1, C4ST-2), and all 
three sulfotransferases (C4ST-1, C4ST-2, C46ST).  Successful knockdown was verified 
by qRT-PCR.  In addition qRT-PCR for all three genes was performed on all conditions 
to verify that the observed decrease mRNA was specific to the targeted mRNA (Figure 
3.3).  Each PCR reaction was run in triplicate and significance from control was 
determined using the Student’s T-test.  For all conditions the mRNA levels for the CSSTs 
corresponding to the siRNA treatment were significantly different than control (p<0.05) 
and <15% of the control.  The mRNA for the other CSSTs were at levels comparable to 
 32 
the control, indicating successful specific knockdown (only C4ST-1 mRNA levels in the 





Figure 3.3.  CSST mRNA Expression.   A) C4ST-1 mRNA is specifically silenced in the 
three conditions receiving C4ST-1 siRNA.  B) C4ST-2 mRNA is specifically silenced in 
the three conditions receiving C4ST-2 siRNA.  C) C46ST mRNA is specifically silenced 
in the two conditions receiving C46ST siRNA.  For all samples where silencing is 






ELISA for Quantification of Total CS-GAG Content 
In the previous section it was verified by qRT-PCR that the gene expressions of 
the CSSTs are being silenced; however, the absence of an antibody specific to the 
targeted CSSTs makes it difficult to verify successful knockdown on the protein level.  
Nevertheless, reduction in the total amount of GAGs secreted by the astrocytes could be 
measured using a CS-56 ELISA, which specifically measures CS-GAGs.   
In the first set of experiments, all CM was collected 72 hours after the first 
transfection.  A CM sample treated with chABC was used at a positive control.  
Significance from control was determined using the Student’s T-test.  Results show a 
slight decrease in CS-GAG sulfation for all siRNA treated samples; however, the only 
condition that was significantly different from the control was the triple knockdown 
(Figure 3.4). 
Given that it takes about 24 hours for significant gene knockdown to occur, it is 
conceivable that CS-GAGs produced in the first 24 hours dominate, or effectively dilute, 
CS-GAGs produced later.  To address this possibility, the astrocyte media was changed 
24 hours after transfection and then collected 48 hours later.  Total CS-GAG content in 
this media was compared to those in media that was not changed and collected after 72 
hours (Figure 3.5).  The results of this experiment showed that after 72 hours, the CS-56 
concentration in CM from the siRNA treated astrocytes (only triple knockdown was 
assayed) was about 60% that of control astrocytes (p<0.05), whereas when there was no 
media change there was no difference in the CS-56 intensity between the groups 
(p>0.05).  These results are contradictory to the previous experiment, where in the 
absence of a media change the CS-56 intensity in the triple knockdown was significantly 
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less than the control cells.  The astrocytes used in this experiment were of a much later 
passage (P = 12 compared to P = 4-6) and, since PCR was not done to verify knockdown, 
it is conceivable that transfection efficiency, and hence the level of protein knockdown, 




Figure 3.4 CS-GAG ELISA I. The total amount of CS-GAGs in the CM was determined 
by performing a CS-56 ELISA on the CM samples. ** indicates significant difference to 







Figure 3.5.  CS-GAG ELISA  II. Media was changed after 24 hours and the total amount 
of CS-GAGs in the CM when was determined by CS-56 ELISA.  In this experiment there 
were six conditions: Control (no media change), Control (media collected at 24 hours), 
Control (media change at 24 hours, media collected at 72 hours), Triple KD (no media 
change), Triple KD (media collected at 24 hours), and Triple KD (media change at 24 







Neurite Guidance Spot Assays 
It has been hypothesized that specific CS-GAGs contribute more to CSPG- 
mediated inhibition of neurite outgrowth, and, therefore, preventing expression of these 
CS-GAGs by knocking down their respective CSSTs will alleviate the inhibitory 
properties of conditioned astrocyte media.  To test this hypothesis, a neurite guidance 
spot assay was performed.  CM collected from control and siRNA treated astrocytes 
(from experiment where media was NOT changed at 24 hours) was concentrated (to a 
final total protein concentration of 1.2mg/mL) and spotted onto PLL coated glass 
coverslips, creating an interface between PLL and the proteins found within the 
conditioned media, including many CSPGs.  Texas Red was mixed with the CM in order 
to visualize the PLL/protein boundary.  Primary cortical neurons were cultured on the 
coverslips for 48 hours and fixed and stained with anti-MAP2 antibody.  Montages at 
20X magnification were taken for image analysis.  To verify that CSPGs from the 
conditioned media did adhere to the coverslip and that Texas Red was sufficient in 
representing the boundary, separate spots using control astrocyte CM were made.  The 
coverslips were fixed with 4% paraformaldehyde and stained with CS-56, an antibody 
specific to CS-GAGs.  Fluorescent images at 10X magnification were taken of the spot 
using both Texas Red and FITC filters.  To visualize the colocalization of Texas Red and 
CS-56 images were overlaid in Adobe Photoshop (Figure 3.6).  There was a strong CS-56 
signal throughout the spot, especially along the edge, and CS-56 staining colocalized with 
Texas Red, demonstrated that the boundary delineated by Texas Red is adequate to use in 
the neurite outgrowth assays. 
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Figure 3.6.  Colocalization of CS-56 and Texas Read. To confirm that the spots 
contained CS-GAGs, and that the Texas Red boundary is the same as the CS-GAG 
boundary spots using control astrocyte media stained with CS-56.  Overlaid images show 
that Texas Red and CS-56 staining are colocalized, ensuring that the Texas Red boundary 
is adequate to use in outgrowth assays.     
 
Percent crossing was determined by dividing the number of neurites that cross 
over onto the spot by the total number of neurites within the distance of the size of one 
soma of the boundary.  Figure 3.7 demonstrates representative images of a neurite not 
crossing (Figure 3.7A) and a neurite crossing (Figure 3.7B).   Six coverslips were assayed 
per condition and significance from control was determined using the Student’s T-test.  
For neurons grown on the spots made of control CM, 43±3% of the neurites crossed from 






Figure 3.7.  Neurite Guidance Spot Assays: Representative Images.  MAP-2 stained 
neurons (green) grown on coverslips spotted with conditioned astrocyte media.  Texas 
Red was added to the media for visualization purposes (red).  Neurites A) not crossing 




Figure 3.8.  Neurite Guidance Spot Assays: Quantification of Crossing.  Percent crossing 
was determined by dividing the number of neurites that cross over onto the spot by the 
total number of neurites within the distance of the size of one soma of the boundary.  
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It is evident that CSPGs and CS-GAGs play a role in the regenerative failure of 
the CNS, though the exact mechanism through which this inhibition occurs remains 
unclear.  Previous work has shown that CS-GAGs inhibit neurite outgrowth in the 
absence of a core protein, and that the degree of inhibition is dependent on the position 
and extent of sulfation, with the dual sulfated CS-GAG, CS-46, being the most inhibitory 
followed by CS-4 (Gilbert et al., 2005).  Furthermore, treatment with sodium chlorate, 
which prevents CS-GAG sulfation, alleviates the inhibitory properties of CSPGs (Smith-
Thomas et al., 1995). With such evidence implicating that sulfation may be at least partly 
responsible for regenerative failure in the CNS, we hypothesized that neurite outgrowth 
could be promoted through modulating the sulfation patterns of CSPGs secreted by 
astrocytes.  To test this hypothesis, we knocked down various CSSTs, the enzymes 
responsible for CS-GAG sulfation, in primary rat astrocytes with the intention of 
controlling the sulfation profile of the CSPGs produced by these cells.  Specifically, we 
chose to target the three enzymes responsible for sulfating the two most inhibitory CS-
GAGs to CNS regeneration: the chondroitin 4,6- sulfotransferase, C46ST, and the 
chondroitin 4-sulfotransferases C4ST-1 and C4ST-2.     
The ability to increase the regenerative potential of CNS neurons through the 
modification of sulfation patterns in the glial scar has important clinical implications.  
The formation of the glial scar, consisting mainly of CSPGs, is the primary cause of 
regenerative failure in CNS regeneration.  However, preventing glial scar formation, 
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either by inhibiting the proliferation of reactive astrocytes (Myer et al., 2006) or 
administering anti-TGF -1 antibodies (King et al., 2004), causes further secondary 
damage and, in turn, results in a greater lesion volume.  Therefore, an effective therapy 
must overcome inhibition caused by the glial scar without disrupting its integrity and, 
consequently, its favorable properties.  In principle, this may be accomplished by 
controlling sulfation content.    
Although targeting the CS-GAG chain biosynthetic pathway may be successful in 
controlling the inhibitory properties of the glial scar, there are several issues that could 
arise with this approach.  One concern is that the targeted enzyme may have multiple 
activities and knocking down the protein, and in turn its other functions, may result in 
undesirable side effects.  In principle, this should not be a problem with the enzymes 
explored herein, as the only known role of CSSTs is their chondroitin sulfating function 
(www.ncbi.nlm.nih.gov/sites/entrez?db=gene, 2008).    A second concern is that more 
than one isoform of the protein may exist which may compensate for the knocked down 
protein.  Given that there are seven known CSSTs, three of which are 4-sulfating, it is 
possible that this problem could arise.  Not only may one isoform compensate for another 
with the same sulfating function, another type of CSST may compensate causing an 
increase in an alternate sulfation pattern.  Knocking down all seven enzymes would be 
very difficult because the siRNA dose necessary to successfully accomplish this is most 
likely cytotoxic.  Assuming that the second scenario does not occur, significant 
improvement in CNS regeneration might be achieved by targeting only two of the seven 
CSSTs.  Even though there are three isoforms of C4ST, only two are present in the CNS, 
and because CS-46 is produced by adding a 6-sulfate to an already present CS-4, the 
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overall levels of CS4,6 and CS-4 should be concomitantly reduced by knocking down 
C4ST-1 and C4ST-2.   
SiRNA are appealing candidates as therapeutic agents given their high specificity 
and ability to control gene function using a naturally occurring cellular pathway. There 
are, however, potential downsides to this approach.  For instance, when targeting a 
multicellular environment, such as the CNS, it is difficult to ensure transfection of the 
appropriate cell type.  Ubiquitous cellular uptake of siRNA would not only decrease the 
knockdown efficiency in target cells, but could also potentially cause detrimental side 
effects in other cells.  Cellular targeting could  be accomplished by modifying the siRNA 
or the delivery vehicle with a ligand to a cell specific receptor (McNamara et al., 2006).  
Additionally, the duration of knockdown must be taken into consideration when using 
siRNA.   Although one strand of siRNA is capable of degrading many strands of mRNA, 
its effects are still transient.  In vitro it has been shown that with a single dose of siRNA, 
mRNA levels  return to control levels 96 hours after transfection (Laabs et al., 2007).  
Appropriate duration may be accomplished using a slow release delivery system, such as 
degradable polymeric microparticles or lipid microtubules (Khan et al., 2004).    
Furthermore, the mode of siRNA delivery may provoke an immune reaction, causing 
further damage.     
Unfortunately, the in vitro neurite guidance assay demonstrated no decrease in 
inhibition caused by CM from siRNA treated astrocytes compared to CM from control 
astrocytes.   Although these results contradict our hypothesis, it cannot be unambiguously 
concluded that modulating sulfation does not affect the inhibitory properties of glial scar.  
There are several explanations for why the expected decrease in inhibition was not 
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observed in our studies.  First, while spot assays using non-conditioned, serum free media 
had significantly more crossing than the Control Condition assay (data not shown), the 
difference was not substantial (<10% difference), potentially indicating that an 
insufficient amount of CSPGs were produced by control astrocytes.  Stimulating the 
astrocytes with TGF  has been shown to significantly increase CSPG production in 
astrocytes (Smith and Strunz, 2005), which in turn should increase the inhibition caused 
by the CM.  Alternatively, it is possible that a sufficient amount of CSPGs was present in 
the media, but there was not a significant difference in the CS-GAG content in the 
various media samples because the media was not collected at the appropriate time point.  
That is, the concentration of the CSPGs produced before the siRNA took effect may be 
greater than the concentration of the CSPGs produced after.  Moreover, it is also 
conceivable that neurons used were not appropriate for the spot assay.  E18 cortical 
neurons were chosen as the model system because the dissection and culture protocol has 
been well established in the lab, and previous findings indicate that the length of neurites 
from these cells grown on CSPGs is shorter than cells grown on control substrates 
(Dergham, 2002).  However, the regenerative capacity of these cells may be too great, 
and the assay may be more effective using an alternative cell types, such as post-natal 





Optimization of Collection of Conditioned Media after Transfection 
 To fully understand the importance of sulfation in CSPG-mediated neurite 
outgrowth, there are several adjustments to the experiments that can be made.  Most 
importantly, the optimal time point of media collection after siRNA delivery must be 
determined.  It is possible that no difference in neurite outgrowth between the 
experimental groups in the spot assay was observed because there was no significant 
difference in the sulfation content of the media.  That is, the CSPGs produced before 
CSST silencing may be overpowering the CSPGs produced thereafter.  SiRNA induced 
gene knockdown can be detected 24 hours after transfection, and possibly even earlier.  
However, it is uncertain how gene knockdown correlates to a decrease in CSST protein 
expression and in turn CS-GAG sulfation.  To characterize the kinetics of CSST 
knockdown, sulfation profiles of CM from various time points can be determined using 
HPLC (details explained below). 
 
Cytokine Stimulation 
 Previously, it has been shown that CSPG production is upregulated in astrocytes 
in vitro when they are stimulated with various cytokines (Smith and Strunz, 2005).  One 
explanation to why there is no significant difference in the inhibition to neurite outgrowth 
caused by the CM of the siRNA treated cells compared to that of control CM is that the 
astrocytes are not secreting adequate levels of CSPGs and therefore the CM from control 
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astrocytes is not significantly inhibitory.  Therefore, increasing CSPG production through 
stimulating the astrocytes to promote CSPG secretion may increase the inhibition caused 
by the control CM.  Additionally, the presence of cytokines will closer mimic the 
environment present after injury. 
 
HPLC to Determine Sulfation Profile 
Although an ELISA is capable of detecting changes in the total amount of CS-
GAGs secreted by astrocytes, it cannot differentiate between the various sulfated GAGs, 
and, therefore, is unable to demonstrate which CS-GAGs are contributing to the total 
content.  In future studies we would like to complete a sulfation profile of the CM to 
ensure that there is a decrease in expression of CS-GAGs corresponding to the CSSTs 
that are being silenced.  Additionally, the possibility that there is an increase in the 
concentration of other sulfated GAGs to compensate for the CS-GAGs that are being 
suppressed must be explored.  This profiling can be achieved using high performance 
liquid chromatography (HPLC).   
 
Addition of Controls in Neurite Guidance Spot Assay 
 To verify that the neurite guidance spot assay is effective in assessing how 
inhibitory the CM is, further controls must be included.  One necessary positive control is 
chABC treated CM from control astrocytes.  Previously it has been shown that neurons 
grown in the presence of chABC treated astrocytic CM exhibit improved neurite 
outgrowth (Laabs et al., 2007) and therefore the same outcome is expected to occur in 
this experimental system.  An additional positive control is CM from astrocytes treated 
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with chlorate, a chemical that inhibits ATP sulphurylase, thereby reducing CS-GAG 
sulfation (Hoogewerf et al., 1991).  This control will show the effects of non-sulfated 
CSPGs on neurite outgrowth.  A negative control that must be included is spots made 
from a known concentration of aggrecan or another intact CSPG.  This control will verify 
that the spots are effectively inhibiting neurite outgrowth.    
 
Delivery of siRNA in an Injury Model 
 Once we demonstrate that modulation of CS-GAG sulfation decreases CSPG-
mediated inhibition of neurite outgrowth in vitro, the feasibility of using this approach in 
vivo will be explored.  More specifically, CSST siRNA will be delivered to a spinal cord 
injury model.    Given that the glial scar takes several weeks to fully form (Fawcett and 
Asher, 1999), the siRNA will be slowly released into the area of injury over this time 
course using lipid microtubules or polymeric microparticles (Khan et al., 2004).  Prior to 
in vivo delivery of the siRNA, in vitro release assays will be performed to determine the 
appropriate loading concentration of the vehicles as well as the number of vehicles to 
administer.  Astrocytes will be transfected with the released siRNA to verify that it is 
effective after release.  Once this is determined the siRNA will be administered in vivo.  
Neurite outgrowth into the glial scar will be examined through histological analysis along 
with functional recovery through behavioral tests. 
A potential issue that may arise with the administration of siRNA in vivo is that 
the CNS is a multicellular environment and therefore it may be difficult to ensure that 
only the astrocytes are being transfected.  Another possible complication is that 
transfection efficiency may be low without a transfection reagent.  Both issues may be 
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solved through modifying the siRNA or the delivery vehicle with a ligand to a cell 
specific receptor (McNamara et al., 2006).  This should increase both cell specificity and 
cellular uptake. 
 
Determine How Effective C4ST siRNA is in Reducing CS-4,6 Levels 
To minimize the total concentration of siRNA delivered to the cells, the feasibility 
of using only C4ST siRNA will be explored.  Significant improvement in CNS 
regeneration may be achieved through targeting only C4ST-1 and C4ST-2, the two 
C4STs present in the CNS.  CS-46 is produced by adding a 6-sulfate to an already present 
CS-4, therefore it may be possible to concomitantly reduce expression of CS-4 and CS-
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